New insider activity at Intellia Therapeutics ( (NTLA) ) has taken place on October 3, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael P Dube, the Vice President and Chief Accounting Officer of Intellia Therapeutics, has recently sold 1,871 shares of the company’s stock. This transaction amounts to a total value of $32,517.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics shows strong technical momentum and promising clinical trial progress, which are significant positives. However, the company’s financial performance is challenged by high R&D expenses and negative cash flows, typical for a biotech firm in development stages. The valuation reflects current unprofitability, and while the earnings call was positive, it highlighted some operational risks.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
YTD Price Performance: 67.27%
Average Trading Volume: 5,283,634
Technical Sentiment Signal: Buy
Current Market Cap: $2.01B